The high court today declined to hear their appeal of a ruling that let Actavis Inc. (ACT) and Amphastar Pharmaceuticals Inc. sell the copycat medicine while a patent-infringement case is pending in federal court. The patent covers a way to analyze the drug during the manufacture process to ensure it follows certain quality controls required by regulators.
Market Data 
Markets 
AI
